- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
11 result(s) found for: Antiallergic.
Displaying page 1 of 1.
| EudraCT Number: 2005-000025-35 | Sponsor Protocol Number: Al0204AV | Start Date*: 2005-04-05 |
| Sponsor Name:Allergopharma Joachim Ganzer KG | ||
| Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of... | ||
| Medical condition: IgE-mediated allergic diseases including allergic rhinitis/rhinoconjunctivitis, allergic bronchial asthma (GINA I and II) triggered by birch pollen allergens | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) FI (Completed) SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-000934-11 | Sponsor Protocol Number: Al0106ac | Start Date*: 2006-08-11 |
| Sponsor Name:Alllergopharma Joachim Ganzer KG | ||
| Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacacy of a specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparatio... | ||
| Medical condition: IgE-mediated allergic disease in adults manifested as rhinitis/ rhinoconjunctivitis and/or allergic asthma bronchiale (GINA I and II) triggered by non eliminable house dust mite allergens. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-002835-27 | Sponsor Protocol Number: DRP-05-12 | Start Date*: 2012-09-07 |
| Sponsor Name:Dr. Ritsert Pharma | ||
| Full Title: Double-blind, randomized clinical study to determine the efficacy of Anestherit® 10% on histamine-induced pruritus and UVB-light induced slight sunburn in healthy subjects. | ||
| Medical condition: Histamine-induced pruritus UVB-light-induced slight sunburn | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-002350-63 | Sponsor Protocol Number: SL300/2004/002/D | Start Date*: 2004-11-19 |
| Sponsor Name:Stallergenes GmbH & Co.KG | ||
| Full Title: Efficacy and Safety of Sublingual Immunotherapy with Ultra-Rush Titration in Children with Allergic Rhinoconjunctivitis to Tree Pollen, a Multicentre DBPC Trial | ||
| Medical condition: Allergic rhinitis against birch pollen | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-004522-10 | Sponsor Protocol Number: Lais-Amb-11 | Start Date*: 2012-05-06 | |||||||||||
| Sponsor Name:LOFARMA | |||||||||||||
| Full Title: Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia | |||||||||||||
| Medical condition: rhinoconjunctivitis allergic to ragweed pollen | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001029-84 | Sponsor Protocol Number: AL0702rB | Start Date*: 2007-08-30 | ||||||||||||||||
| Sponsor Name:Allergopharma Joachim Ganzer KG | ||||||||||||||||||
| Full Title: A multicentre randomised, placebo-controlled, double-blind pivotal clinical trial for the evaluation of safety and efficacy of specific of immunotherapy with an aluminium hydroxide-adsorbed hypoall... | ||||||||||||||||||
| Medical condition: ICD classification code: J45.0 and J30.1 | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) SE (Completed) FI (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2004-000083-27 | Sponsor Protocol Number: GT-08 | Start Date*: 2004-09-19 |
| Sponsor Name:ALK-Abelló A/S | ||
| Full Title: A randomised, parallel-group, double-blind, placebo-controlled Phase III trial assessing the efficacy and safety of ALK Grass Tablet Phleum pratense in subjects with seasonal grass pollen induced r... | ||
| Medical condition: Rhinoconjunctivitis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) IT (Completed) ES (Completed) AT (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-004916-79 | Sponsor Protocol Number: SMART_10 | Start Date*: 2013-02-26 | |||||||||||
| Sponsor Name:Lofarma S.p.A. | |||||||||||||
| Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS® Grass tablets for patients with grass pollen-induced allergic rhinoconjunctivitis, a phase III study | |||||||||||||
| Medical condition: Patients suffering from allergic rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002129-43 | Sponsor Protocol Number: SMART_7 | Start Date*: 2013-12-09 | |||||||||||
| Sponsor Name:Lofarma S.p.A. | |||||||||||||
| Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS®Birch-Alder tablets for patients with tree pollen-induced allergic rhinoconjunctivitis A Phase III study | |||||||||||||
| Medical condition: Patients suffering from allergic rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-004185-14 | Sponsor Protocol Number: CDPG103ADE01 | Start Date*: 2012-02-29 | |||||||||||||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||||||||||||
| Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intraseasonal specific short-term immunotherapy with depigmented glutaraldeh... | |||||||||||||||||||||||
| Medical condition: Allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2010-018562-23 | Sponsor Protocol Number: 6078-PG-PSC-169 | Start Date*: 2010-09-15 | |||||||||||||||||||||
| Sponsor Name:LETI Pharma GmbH | |||||||||||||||||||||||
| Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivi... | |||||||||||||||||||||||
| Medical condition: Allergic rhinitis and/or allergic rhinoconjunctivitis with or without intermittent asthma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: CZ (Prematurely Ended) BG (Ongoing) HU (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.